CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0042 (clinicaltrials.gov NCT No: NCT00695786)
Title:A Phase II Study of Revlimid in Combination with Rituximab as Initial Treatment for Patients with Indolent Non-Hodgkin’s Lymphoma (NHL)
Principal Investigator:Felipe Samaniego
Treatment Agent:Lenalidomide; Rituximab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if revlimid (lenalidomide)
in combination with rituximab in previously untreated indolent non-Hodgkin's
lymphoma can control the disease. The safety of this combination will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Lenalidomide
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Celgene
Return Visit:Check-up visits day 1 of all cycles. Patients will be evaluated every 3 months
for one year, every 6 months for 1 year and then yearly with CT neck, thorax,
abdomen, and pelvis and other studies as recommended by the treating
physician.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Felipe Samaniego
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults